ENDOCANNABINOID CEREBROSPINAL FLUID LEVELS IN MIGRAINE 91 4 22. Greco R, Mangione AS, Sandrini G, et al. Effects of anandamide in migraine: data from an animal model. J Headache Pain. 2011;12(2):177-183. 23. Cupini LM, Bari M, Battista N, et al. Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs. Cephalalgia. 2006;26(3):277-281. 24. Greco R, Demartini C, Zanaboni AM, et al. Peripheral changes of endocannabinoid system components in episodic and chronic migraine patients: A pilot study. Cephalalgia. 2021;41(2):185-196. 25. Gallego-Landin I, García-Baos A, CastroZavala A, Valverde O. Reviewing the Role of the Endocannabinoid System in the Pathophysiology of Depression. Review. Front Pharmacol. 2021;12 :762738 26. Peres MFP, Mercante JPP,Tobo PR, Kamei H, Bigal ME. Anxiety and depression symptoms and migraine: a symptom-based approach research. J Headache Pain. 2017;18(1):37. 27. Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry. 2008;41(2):48-53. 28. Hill MN, Ho WS, Hillard CJ, Gorzalka BB. Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents. J Neural Transm (Vienna). 2008;115(12):1673-1679. 29. Onderwater GLJ, van Dongen RM, Harms AC, et al. Cerebrospinal fluid and plasma amine profiles in interictal migraine. Ann Neurol. 2022; 93(4):715-728 30. Louter MA, Pelzer N, de Boer I, et al. Prevalence of lifetime depression in a large hemiplegic migraine cohort. Neurology. 2016;87(22):2370-2374. 31. He B, Di X, Guled F, et al. Quantification of endocannabinoids in human cerebrospinal fluid using a novel micro-flow liquid chromatography-mass spectrometry method. Anal Chim Acta. 2022;1210:339888. 32. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R.2011;45(3):67-% 33. RStudio: integrated development for R. RStudio, Inc.; 2015. http://www.rstudio.com 34. Onderwater GLJ, van Oosterhout WPJ, Schoonman GG, Ferrari MD, Terwindt GM. Alcoholic beverages as trigger factor and the effect on alcohol consumption behavior in patients with migraine. Eur J Neurol. 2019;26(4):588-595. 35. Ashina S, Terwindt GM, Steiner TJ, et al. Medication overuse headache. Nat Rev Dis Primers. 2023;9(1):5. 36. Gouveia-Figueira S, Goldin K, Hashemian SA, et al. Plasma levels of the endocannabinoid anandamide, related N-acylethanolamines and linoleic acid-derived oxylipins in patients with migraine. Prostaglandins Leukot Essent Fatty Acids. 2017;120:15-24. 37. Buczynski MW, Parsons LH. Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls. Br J Pharmacol. 2010;160(3):423-442. 38. Lehmann R. From bedside to bench-practical considerations to avoid pre-analytical pitfalls and assess sample quality for high-resolution metabolomics and lipidomics analyses of body fluids. Anal Bioanal Chem. 2021;413(22):55675585. 39. Jonasdottir HS, Brouwers H,Toes REM, IoanFacsinay A, Giera M. Effects of anticoagulants and storage conditions on clinical oxylipid levels in human plasma. Biochimica et biophysica acta Molecular and cell biology of lipids. 2018;1863(12):1511-1522. 40. van Dongen RM, Zielman R, Noga M, et al. Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis. Cephalalgia. 2017;37(1):49-63. 41. Hillard CJ. Circulating Endocannabinoids: From Whence Do They Come and Where are They Going? Neuropsychopharmacology. 2018;43(1):155-172. 42. Engeli S,Böhnke J,Feldpausch M,et al.Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54(10):2838-2843.
RkJQdWJsaXNoZXIy MTk4NDMw